Scarica l'app Stockscreener
21.31
0.19%
0.04
Dopo l'orario di chiusura:
21.26
-0.05
-0.23%
Precedente Chiudi:
$21.27
Aprire:
$21.29
Volume 24 ore:
5.10M
Relative Volume:
1.21
Capitalizzazione di mercato:
$2.20B
Reddito:
$133.67M
Utile/perdita netta:
$-151.76M
Rapporto P/E:
-14.35
EPS:
-1.4854
Flusso di cassa netto:
$-124.86M
1 W Prestazione:
+0.52%
1M Prestazione:
+87.75%
6M Prestazione:
+199.30%
1 anno Prestazione:
+144.94%
Intervallo 1D:
$21.26
$21.32
Intervallo di 1 settimana:
$21.19
$21.43
Portata 52W:
$5.635
$21.43
Day One Biopharmaceuticals Inc Stock (DAWN) Company Profile
Nome
Day One Biopharmaceuticals Inc
Settore
Industria
Telefono
650 484-0899
Indirizzo
1800 SIERRA POINT PARKWAY, SUITE 200, BRISBANE
Compare DAWN vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DAWN
Day One Biopharmaceuticals Inc
|
21.31 | 2.20B | 133.67M | -151.76M | -124.86M | -1.4854 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Day One Biopharmaceuticals Inc Stock (DAWN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-10 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2026-01-13 | Ripresa | TD Cowen | Buy |
| 2025-08-19 | Iniziato | Piper Sandler | Overweight |
| 2024-10-09 | Reiterato | Needham | Buy |
| 2024-08-01 | Aggiornamento | BofA Securities | Underperform → Buy |
| 2024-04-24 | Reiterato | Needham | Buy |
| 2023-04-25 | Downgrade | BofA Securities | Buy → Underperform |
| 2023-02-08 | Iniziato | CapitalOne | Overweight |
| 2023-02-03 | Iniziato | Oppenheimer | Perform |
| 2022-12-15 | Iniziato | H.C. Wainwright | Buy |
| 2022-12-14 | Iniziato | Needham | Buy |
| 2022-12-05 | Iniziato | Goldman | Buy |
| 2022-12-01 | Iniziato | BofA Securities | Buy |
Mostra tutto
Day One Biopharmaceuticals Inc Borsa (DAWN) Ultime notizie
DAWN stock jumps 66% on $2.5B buyout offer from Servier - MSN
Servier All Cash Deal Reframes Day One Biopharmaceuticals Valuation Story - Sahm
Servier Acquires Day One Biopharmaceuticals for $2.5B, Betting on Tovorafenib and the Pediatric Glioma Frontier - Oncodaily
symbol__ Stock Quote Price and Forecast - CNN
Halper Sadeh LLC is Investigating Whether DAWN, SEM, EWCZ, FONR are Obtaining Fair Deals for their Shareholders - GlobeNewswire Inc.
Are DAWN, TALK, UNF Obtaining Fair Deals for their Shareholders? – Company Announcement - Financial Times
The M&A Class Action Firm Encourages $hareholders to Contact Monteverde Concerning the Merger—DAWN, SEM, FONR, and EWCZ - Carroll County Mirror-Democrat
Day One Biopharmaceuticals gains amid takeover speculation - MSN
A Look At Day One Biopharmaceuticals (DAWN) Valuation After Recent Share Price Momentum - Yahoo Finance
This VICI Properties Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Wednesday - Benzinga
Day One Biopharmaceuticals (NASDAQ:DAWN) Given "Neutral" Rating at JPMorgan Chase & Co. - MarketBeat
JPMorgan downgrades Day One Biopharmaceuticals stock rating on Servier acquisition - Investing.com Canada
Servier to acquire Day One Biopharmaceuticals for $2.5 billion - Investing.com Nigeria
Day One Biopharmaceuticals Acquires Mersana Therapeutics: Key Financial Details, Purchase Price, and Pro Forma Impact - Minichart
This Day One Biopharmaceuticals Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Tuesday - Benzinga
Day One Biopharmaceuticals' (DAWN) "Neutral" Rating Reiterated at HC Wainwright - MarketBeat
Day One Biopharma : DAWN - 24/7 Wall St.
Day One Biopharmaceutical (DAWN) Downgraded to Neutral by HC Wai - GuruFocus
HC Wainwright & Co. downgrades Day One Biopharmaceuticals (DAWN) - MSN
Day One (DAWN) soars 100% on $2.5-billion merger - MSN
Are DAWN and TALK Obtaining Fair Deals for their Shareholders? - Finviz
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Day One Biopharmaceuticals, Inc. Buyout: Why Servier’s $2.5 Billion Ojemda Deal Matters Now - TechStock²
DAWN Stock Jumps 66% on $2.5B Buyout Offer From Servier - TradingView
DAWN Stock Downgraded by Wedbush with Price Target Adjustment | - GuruFocus
Wedbush Reaffirms Neutral Rating for Day One Biopharmaceuticals (NASDAQ:DAWN) - MarketBeat
Day One Biopharmaceuticals Touts OJEMDA Sales Surge, Sets $225M-$250M 2026 Outlook at TD Cowen - MarketBeat
Servier acquires International Biotech's Day One for USD2.5 billion - marketscreener.com
Day One (DAWN) Soars 100% on $2.5-Billion Merger - Yahoo Finance
Day One Biopharma Earnings Call Highlights Ojemda Surge - TipRanks
Top Small Cap Stocks To Add to Your WatchlistMarch 7th - MarketBeat
Key deals this week: Diana Shipping, Day One Biopharmaceuticals, Hudbay Minerals and more - Seeking Alpha
Pharmaceutical Stocks To ResearchMarch 7th - MarketBeat
JonesTrading Maintains Buy Rating on Day One Biopharmaceuticals (DAWN) Following Ojemda’s FDA Approval - MSN
Knott David M Jr Grows Position in Day One Biopharmaceuticals, Inc. $DAWN - MarketBeat
Day One Biopharmaceuticals (NASDAQ:DAWN) Rating Lowered to "Hold" at Wedbush - MarketBeat
Servier to acquire Day One Biopharmaceuticals for $2.5 billion By Investing.com - Investing.com Canada
Day One Biopharmaceuticals stock hits 52-week high at 21.12 USD - Investing.com Canada
Day One (DAWN) Climbs to 3-Year High on $2.5-Billion Merger - Yahoo Finance
Day One Biopharmaceuticals (DAWN) Stock Surges 66% on Servier's $2.5 Billion Acquisition Deal - International Business Times Australia
Servier to buy Day One Biopharma for $2.5 billion in tumor treatment push - ET Pharma
Servier Acquiring Day One Biopharmaceuticals For About $2.5 Billion - Pulse 2.0
Day One Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Day One Biopharmaceuticals, Inc.DAWN - Business Wire
User - The Chronicle-Journal
Day One Biopharmaceuticals, Inc. (DAWN): A Hold Rating Amid Emerging Potential - 富途牛牛
DAWN: Cowen Downgrades Day One Biopharmaceuticals to Hold March 2026 - Meyka
Servier Adds To Rare Cancers Portfolio With Proposed Day One Buyout - Citeline News & Insights
Day One Biopharmaceuticals (DAWN) Stock Jumps 66% After Servier Acquisition Deal - MEXC
JonesTrading Reiterates Hold Rating for Day One Biopharmaceuticals (NASDAQ:DAWN) - MarketBeat
Why A 'White Knight' Could Still Fight For Day One Bio - Investor's Business Daily
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Day One Biopharmaceuticals, Inc. (DAWN) - marketscreener.com
Day One Biopharmaceuticals Inc Azioni (DAWN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):